The kidney is a quiet organ. It does not page a surgeon or set off an alarm. So when a patient's kidneys begin to fail during or after a major procedure, the first sign often arrives a day later, in a lab result, after the damage is already done. Acute kidney injury - AKI - is one of the most common complications of cardiac surgery, contrast-based heart procedures, and intensive care, and it lengthens hospital stays, raises costs, and worsens outcomes.
CardioRenal Systems, a medical device company based in Milford, Massachusetts, built its business around a single idea: what if hydration during those high-risk moments could be automated and precise, rather than estimated by hand? Its answer is the RenalPro System, sold outside the United States as RenalGuard. The console continuously measures a patient's urine output and adjusts the intravenous fluids they receive in milliliter increments - roughly a fifth of a teaspoon at a time - keeping the patient hemodynamically stable and the kidneys protected against both over- and under-hydration.
The approach is called balanced forced diuresis. The engineering that makes it reliable is protected by a portfolio of 20 patents and pending applications. And the clinical case behind it is not theoretical: in a 220-patient randomized, controlled trial known as the KIDNEY study, RenalPro Therapy reduced AKI by 52% compared with standard care, with no reported adverse events.
